📊 CVS Key Takeaways
Is CVS HEALTH Corp (CVS) a Good Investment?
CVS demonstrates stable revenue growth of 7.8% YoY and positive free cash flow generation of $7.8B, supporting dividend and debt service capacity. However, profitability metrics are severely compressed with net margins at 0.4% and ROE at 2.4%, indicating operational challenges in converting sales to earnings despite top-line expansion.
CVS Health shows solid scale and resilient top-line growth, supported by meaningful operating cash flow and positive free cash flow generation. However, the quality of that growth is weakened by extremely thin margins, flat net income, and a sharp decline in diluted EPS, while below-1.0 liquidity ratios limit flexibility. Fundamentally, the business appears stable but not strong enough to justify a more bullish view until profitability improves.
Why Buy CVS HEALTH Corp Stock? CVS Key Strengths
- Strong revenue growth of 7.8% YoY demonstrates market demand and operational scale
- Solid free cash flow generation of $7.8B provides liquidity for debt reduction and shareholder returns
- Reasonable interest coverage ratio of 6.5x suggests manageable debt servicing capability
- Substantial asset base of $253.5B indicates established market position and operational infrastructure
- Revenue growth of 7.8% YoY at very large scale indicates durable demand across the business
- Operating cash flow of $10.64B and free cash flow of $7.81B provide internal funding capacity
- Leverage appears manageable with debt/equity of 0.85x and interest coverage of 6.5x
CVS Stock Risks: CVS HEALTH Corp Investment Risks
- Extremely low net profit margin of 0.4% indicates severe profitability compression and minimal earnings per dollar of revenue
- Diluted EPS declined 62% YoY while net income remained flat, signaling significant earnings deterioration and potential share dilution
- Current ratio of 0.84x and quick ratio of 0.63x suggest liquidity constraints; current liabilities exceed current assets
- High long-term debt of $63.7B relative to equity of $75.2B limits financial flexibility for strategic investments
- Anemic return metrics with ROE of 2.4% and ROA of 0.7% indicate capital is not generating sufficient returns
- Profitability is very weak, with 5.3% gross margin, 1.2% operating margin, and 0.4% net margin
- Diluted EPS fell 62.0% YoY, signaling pressure on earnings quality despite revenue growth
- Liquidity is tight with a 0.84x current ratio and 0.63x quick ratio
Key Metrics to Watch
- Net profit margin trend - critical to assess if 0.4% represents bottom or continued compression
- Free cash flow sustainability - must monitor if $7.8B level can be maintained amid margin pressures
- Gross margin stability - current 5.3% is razor-thin and vulnerable to cost inflation or competitive pricing pressure
- Debt reduction progress - need to track whether the company uses FCF to delever given high absolute debt levels
- Operating leverage - assess whether revenue growth translates to operating income expansion going forward
- Operating margin and net margin trend
- Diluted EPS recovery versus revenue growth
CVS HEALTH Corp (CVS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The relatively thin 1.9% FCF margin may limit capital allocation flexibility. The current ratio below 1.0x warrants monitoring of short-term liquidity.
CVS Profit Margin, ROE & Profitability Analysis
CVS vs Consumer Sector: How CVS HEALTH Corp Compares
How CVS HEALTH Corp compares to Consumer sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is CVS HEALTH Corp Stock Overvalued? CVS Valuation Analysis 2026
Based on fundamental analysis, CVS HEALTH Corp shows some fundamental concerns relative to the Consumer sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
CVS HEALTH Corp Balance Sheet: CVS Debt, Cash & Liquidity
CVS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: CVS HEALTH Corp's revenue has grown significantly by 38% over the 5-year period, indicating strong business expansion. The most recent EPS of $6.47 reflects profitable operations.
CVS Revenue Growth, EPS Growth & YoY Performance
CVS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $95.4B | $87.0M | $0.07 |
| Q2 2025 | $91.2B | $1.0B | $0.80 |
| Q1 2025 | $88.4B | $1.1B | $0.88 |
| Q3 2024 | $89.8B | $87.0M | $0.07 |
| Q2 2024 | $88.9B | $1.8B | $1.41 |
| Q1 2024 | $85.3B | $1.1B | $0.88 |
| Q3 2023 | $81.2B | $2.0B | $1.49 |
| Q2 2023 | $80.6B | $1.9B | $1.48 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CVS HEALTH Corp Dividends, Buybacks & Capital Allocation
CVS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for CVS HEALTH Corp (CIK: 0000064803)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CVS
What is the AI rating for CVS?
CVS HEALTH Corp (CVS) has a Combined AI Rating of HOLD from Claude (HOLD) and ChatGPT (HOLD) with 70% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CVS's key strengths?
Claude: Strong revenue growth of 7.8% YoY demonstrates market demand and operational scale. Solid free cash flow generation of $7.8B provides liquidity for debt reduction and shareholder returns. ChatGPT: Revenue growth of 7.8% YoY at very large scale indicates durable demand across the business. Operating cash flow of $10.64B and free cash flow of $7.81B provide internal funding capacity.
What are the risks of investing in CVS?
Claude: Extremely low net profit margin of 0.4% indicates severe profitability compression and minimal earnings per dollar of revenue. Diluted EPS declined 62% YoY while net income remained flat, signaling significant earnings deterioration and potential share dilution. ChatGPT: Profitability is very weak, with 5.3% gross margin, 1.2% operating margin, and 0.4% net margin. Diluted EPS fell 62.0% YoY, signaling pressure on earnings quality despite revenue growth.
What is CVS's revenue and growth?
CVS HEALTH Corp reported revenue of $402.1B.
Does CVS pay dividends?
CVS HEALTH Corp pays dividends, with $3,397.0M distributed to shareholders in the trailing twelve months.
Where can I find CVS SEC filings?
Official SEC filings for CVS HEALTH Corp (CIK: 0000064803) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CVS's EPS?
CVS HEALTH Corp has a diluted EPS of $1.39.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CVS a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, CVS HEALTH Corp has a HOLD rating with 70% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CVS stock overvalued or undervalued?
Valuation metrics for CVS: ROE of 2.4% (sector avg: 18%), net margin of 0.4% (sector avg: 8%). Compare these metrics with sector averages to assess valuation.
Should I buy CVS stock in 2026?
Our dual AI analysis gives CVS HEALTH Corp a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CVS's free cash flow?
CVS HEALTH Corp's operating cash flow is $10.6B, with capital expenditures of $2.8B. FCF margin is 1.9%.
How does CVS compare to other Consumer stocks?
Vs Consumer sector averages: Net margin 0.4% (avg: 8%), ROE 2.4% (avg: 18%), current ratio 0.84 (avg: 1.5).